Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
The New York Eye & Ear Infirmary Genentech |
---|---|
Information provided by: | The New York Eye & Ear Infirmary |
ClinicalTrials.gov Identifier: | NCT00570726 |
This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.
Condition | Intervention | Phase |
---|---|---|
Glaucoma, Open-Angle Failing Bleb Following Trabeculectomy |
Drug: Ranibizumab (Lucentis) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jeffrey Liebmann, MD | 212-477-7540 ext 330 | JML18@earthlink.net |
Contact: John M Purcell, BA | 212-477-7540 ext 302 | jpurcell@nyee.edu |
United States, New York | |
Glaucoma Associates of New York | Recruiting |
New York, New York, United States, 10003 | |
Contact: Elena Ilitchev, MD 212-477-7540 ext 332 Ilitcheve@gmail.com | |
Principal Investigator: Jeffrey Liebmann, MD |
Principal Investigator: | Jeffrey Liebmann, MD | Glaucoma Associates of New York |
Study ID Numbers: | 07.10 |
Study First Received: | December 9, 2007 |
Last Updated: | December 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00570726 |
Health Authority: | United States: Food and Drug Administration |
Glaucoma Eye Diseases Glaucoma, Open-Angle |
Blister Hypertension Ocular Hypertension |